Mesenchymal stem cells added to second-line therapy improve response and failure-free survival in steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A meta-analysis of randomized controlled tr
The addition of MSCs to second-line therapy significantly improves treatment response, reduces chronic GVHD incidence, and prolongs failure-free survival in patients with steroid-refractory aGVHD, with a favorable safety profile. These findings support MSC-based therapy as a promising strategy for this high-risk population.
Authors
- Ying Yan (ORCID: https://orcid.org/0000-0002-3546-3991)
- Jinhong Yang (ORCID: https://orcid.org/0000-0002-8356-835X)
- Rui Zhang (ORCID: https://orcid.org/0000-0001-5691-8329)
- Yameng Zhao
- Man Xiao
- Li Wang (ORCID: https://orcid.org/0000-0003-3722-5986)
- Dan Wang (ORCID: https://orcid.org/0009-0009-8060-9054)
Institutions
- Weifang Medical University (CN)
- Union Hospital (HK)
- Zimmer Biomet (Netherlands) (NL)
- Beijing Emergency Medical Center (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-04
- DOI
- https://doi.org/10.3389/fonc.2025.1704963
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00